Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

FFFrantišek FolberAOAleš ObrVCVít Campr

Discussion

Loading...

Member takes

Overview

Propensity score matching analysis shows CAR-T therapy improves event-free survival in relapsed DLBCL patients, suggesting it may be a vital treatment option.

Key Points

  • To compare survival outcomes between CAR-T therapy and alternative third-line treatments for relapsed/refractory DLBCL.
  • Analyzed 240 r/r DLBCL patients enrolled in the NiHiL project
  • Used propensity score matching to compare CAR-T and alternative therapies
  • Collected clinical parameters and treatment outcomes
  • Matched CAR-T patients show 43.5% event-free survival at 18 months versus 24.7% for alternatives
  • Trend toward improved overall survival in CAR-T group
  • Median follow-up of 20.9 months for living patients

Cite This Study

Folber et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e41dhttps://doi.org/10.1182/blood-2025-3664
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy2025
  2. 2Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic2026
  3. 3CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations
  4. 4CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.2026
  5. 5Real-World Treatment Patterns of Patients with Large B-cell Lymphoma Over Time and into a Post-CAR T Approval Era2026